IL18 and pulmonary arterial hypertension: Elevated circulating levels of inflammatory mediators, like IL‐18, have also been observed in pulmonary arterial hypertension (PAH), which seem to correlate with worse clinical outcome (Cracowski et al., 2014; Ross et al., 2012; Soon et al., 2010).